Compounds for Inhibiting NLRP3 and Uses Thereof
Ventus Therapeutics U.S., Inc.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 63/171,932, filed Apr 7, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,319,319 | Compounds for Inhibiting NLRP3 and Uses Thereof In force · High confidence UsedRemaining | Novo Nordisk A/S and Ventus Therapeutics U.S., Inc. | In force | High confidence | ||
| US 12,281,112 | Compounds for Inhibiting NLRP3 and Uses Thereof In force · Low confidence | Ventus Therapeutics U.S., Inc. | In force | Low confidence | ||
| US 12,351,578 | Compounds for Inhibiting NLRP3 and Uses Thereof In force · Medium confidence | Ventus Therapeutics U.S., Inc. | In force | Medium confidence | ||
| Application 17/679,898 | Compounds for Inhibiting NLRP3 and Uses Thereof Abandoned Abandoned Mar 18, 2024 | Ventus Therapeutics U.S., Inc. | Abandoned | Abandoned Mar 18, 2024 | ||
| Application 18/534,906 | Compounds for Inhibiting NLRP3 and Uses Thereof Abandoned Abandoned Aug 20, 2024 | Ventus Therapeutics U.S., Inc. | Abandoned | Abandoned Aug 20, 2024 | ||
| Application 18/763,302 | Compounds for Inhibiting NLRP3 and Uses Thereof Abandoned Abandoned Mar 4, 2025 | Ventus Therapeutics U.S., Inc. | Abandoned | Abandoned Mar 4, 2025 | ||
| Application 18/891,602 | Compounds for Inhibiting NLRP3 and Uses Thereof Pending Not granted | Ventus Therapeutics U.S., Inc. | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Ventus Therapeutics U.S., Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.